Enhancing Lives by Advancing the Art of Plastic Surgery - R&D DAY PRESENTATION Jamie, Actual Sientra Patient
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Enhancing Lives by
Advancing the Art of
Plastic Surgery
R&D DAY PRESENTATION
Jamie, Actual Sientra Patient
SETTING THE STANDARD FOR PLASTIC SURGERY
Exclusivity to Board-Certified Plastic
01 05 Unrivaled Safety + Clinical Data
Surgeons
02 Brought Shaped Implants to Market 06 Industry-Leading
20-year Platinum20™ Warranty
03 Continued Innovation (5th Gen)
on Broad Portfolio of Silicone Gel Implants
07 Plastic Surgery Consultants Focused
on Practice Growth
04 Advanced AlloX2® the Only Tissue Expander 08 Charitable Giving Programs
with Aspiration Port
2
SIENTRA: EVOLVING INTO A FULL AESTHETICS
COMPANY
Eyes, Ears,
Nose
$1.0
Face, Neck, 8%
Brow Breast
$1.4 $4.0
11% 30%
Toxin/Filler
$3.0
Breast Breast Non-Breast
22%
Augmentation Reconstruction
Body
$3.9
29%
Retail Market Size in Billions of Dollars
* Ronan Solutions, Aesthetic Industry Insights, Dec. 12, 2021. Data on File.
1 Gluteal augmentation (including fat grafting), thigh/other body fat
grafting, Tummy Tuck, liposuction, lipectomy, gastric balloon, excision of
excess skin. 3
SIGNIFICANT ADDRESSABLE MARKET
Near-Term Addressable
Market Opportunity1
(Millions)
§ Significant opportunity for
U.S. Aesthetic Breast Implants $280 growth via deeper
penetration across existing
U.S. Reconstructive Breast Implants $115 markets and entry into new Ex
U.S. markets:
U.S. Tissue Expanders $180
§ Japanese approval in
Scar Management $30 August 2020
§ Health Canada approval
Japan Breast Implants $15
in Q1 2022
Canada Breast Implants $20
Fat Grafting (Breast) $160
Near-Term Addressable Market $800
1 Market size based on company estimates and American Society of Plastic Surgeons annual statics report (2019)
• A leader in Reconstruction
• Grow into a full Aesthetics Company
• Double our revenue in the next 3 years
5
MARKET DYNAMICS
6
TOP TRENDS IN PLASTIC SURGERY: BREAST AESTHETICS
REMAINS #1 REVENUE GENERATOR
5-Year Category Revenues (US)*
Total 5-Year Revenues*
$4.0
Breast $14 B
$3.9
$3.4 $3.4
Body $11B
$3.3
Breast
$3.0 Toxin/Filler $11 B
$2.9
$2.8
Toxin/ Filler
$2.7 Face, Neck, Brow $4 B
$2.5
Eyes, Ears, Nose $3 B
$2.1 $2.1
Body
$1.4
$1.0 $1.0
$0.9 $0.9
Face/Neck/Brow $0.6 $0.6 $0.6
Eyes/Ears/Nose
2018 2019 2020 2021
* Ronan Solutions, Aesthetic Industry Insights, Dec. 12, 2021. Data on File. 7
SINCE COVID IN EARLY 2020, HOSPITAL PURCHASES OF
IMPLANTS/EXPANDERS HAVE SOFTENED
Purchase Volume (units)
Gel Implants & Breast Expanders
800000
700000
-12%
-3% +11%
600000 185946 • COVID may have
167277
-5% continued to impact
174049
164592 hospital access at
500000 152153
local/regional levels
400000 • Implant purchases
declined -4.4% YoY
300000 • Expander purchases
488087
515939 declined at higher
459111 450972 rate of -7.5%
430984
200000
100000
0
2017 2018 2019 2020 2021
Implants Expanders Reference: IQVIA, SMART-Medical Device Supply Edition, Gel Implants &
Breast Expander purchases, Q1 2017-Q4 2021 8
SIENTRA RECONSTRUCTION SHOW STRONG MOMENTUM
GAINS +3.8 SHARE PTS
Sientra Reconstruction Market Share
Based on IQVIA- Hospital Purchase Volume*
15.0%
2021 Market Updates
15%
14% 13.5% • 2021 gel implants & expanders
market estimated at >$220M*
13%
12.9% • Implants: $95M
12%
10.9% • Expanders: $125M
11%
10%
9.7% • Sientra has incrementally gained
9.1%
+3.8 share points share since 2019 closing 2021 at
9%
9.2% 1.4X YoY 13.5%
8%
7.2% • 1.4x vs 2020
7%
• 1.9x vs 2019
6% 6.6%
2019 2020 2021
Implants Expanders All Reconstruction
(blended)
Reference: IQVIA, SMART-Medical Device Supply Edition, Gel
Implants & Breast Expander purchases, Q1 2017-Q4 2021
AESTHETIC BREAST IMPLANT PROCEDURAL VOLUME
2021 AT A 4-YEAR HIGH
Aesthetic Breast Implant Procedural Volume by Procedure Type
Augmentation Revision Aug Mastopexy w/Implants Other
650,000
564,783
+20% 4,698
550,000 +9% 471,387
- 5% Mastopexy
81,745
458,191 433,845 3,862 w/Implants: 14%
450,000 5,409 Mastopexy
64,958
94,836 Mastopexy Mastopexy w/Implants: 14%
w/Implants: 21%
55,979 w/Implants: 13% 153,990 Revision Aug: 27%
350,000
134,050
108,158 Revision Aug: 28%
Revision Aug: 24% 140,710
Revision Aug: 32%
250,000
150,000 324,350 Primary
Primary
255,216 Primary 268,517 Primary Augmentation: 57%
Augmentation: 56% 231,747 Augmentation: 57%
Augmentation: 53%
50,000
-50,000
2018 2019 2020 2021
Ronan Data: February 7, 2022. History & Trends > Breast Procedures > Incl. Augmentation, Mastopexy with implants, and Revision (Removal/Replacement)SIENTRA AUGMENTATION CONTINUES STRONG GAINS IN
2021 WITH 2.2x SHARE GROWTH SINCE 2019
Cosmetic Breast Implants Category | Sientra Share by Year
Based on Procedural Units Shipped1
10.0% 9.5%
ain
+17 pts
9.0%
g
8.0% h are
s
7.0%
2x
6.5%
6.0% Growth in Sientra brand
5.0% 4.7% awareness amongst breast
4.0%
augmentation considerers2
3.0%
• In one year, Sientra brand
2.0%
awareness doubled from 16% to
1.0% 33%, becoming the #2 most
recognized brand2
0.0%
FY 2019 FY 2020 FY 2021
1 Sientra Share - Procedural Units Shipped (includes evaluation units, warranty but excludes sizers and Japan) compared to Ronan Solutions: Primary + Secondary Augmentation Data.
2 Sientra brand awareness and tracking study, February 2022. 11TIMEFRAME TO TREATMENT CUT IN HALF
2020 2020
40 months 4 months
Begins Average time between Seeks Consult Average time between Has BA Surgery
Considering BA when a woman first with Surgeons consultation and surgery
starts thinking about BA
and going in for consult
2022 2022
19 months 8 months
Begins Seeks Consult Has BA Surgery
Considering BA with Surgeons
Reference: January 2022: Sientra Market Research, data on file * Data on file 12SIENTRA GROWTH DRIVERS 2022-23
U.S. Centric /
Untapped Market
Consumer Activation
New/existing account growth:
Digital media connects • Surgeon Education / Training
thousands of patients with Market Penetration • Value-add programs/services
surgeons • Sales structure and support
Consumer Voice
Line Extensions
Int’l Expansion
Influencers drive message of
choice and empowerment Japan, Canada, China
Dermaspan w/ 6 tabs
Low Profile Plus
Sientra Academy
Cutting edge practice Market Builders
management training Consumerization New Products
AlloX2 Pro
Portfinder
Reconstruction
Educate, Support, Connect Broadened Aesthetic
Offering
Fat Grafting
13UNRIVALED SAFETY AND CLINICAL DATA
*
4
*The clinical studies from these manufacturers are not
designed to be compared head-to-head. Each individual
company’s own individual and published rates were
presented
1Stevens WG, Calobrace MB, Alizadeh A, Zeidler KR,
Harrington JL, d’Incelli RC. Ten-year core study data for
Sientra’s Food and Drug Administration - approved round
and shaped breast implants with cohesive silicone gel. Plast
Reconstr Surg. 2018;141(4S):7S-19S.
2Mentor Worldwide LLC. Patient Decision Checklist:
MemoryShape & MemoryGel:
https://www.breastimplantsbymentor.com/MENTOR-
implant-safety-information. Accessed December 2021
3Allergan Sales, LLC. Patient Decision Checklist:
https://www.natrellesurgeon.com/Content/PDF/Augmentati
on_Consent_Form.pdf. Accessed December 2021
4Sientra, Inc. Patient Decision Checklist:
https://sientra.com/app/uploads/2021/10/MDC-0748-R2-
Patient-Decision-Checklist-AUG-v1.pdf. Accessed April 2022
14WHAT MATTERS MOST TO RECON SURGEONS
Current
Importance in Selecting Total
Top-2 Box n=49
Implant Brands
(Table Stakes) Manufacturer is consistent in having an available supply of everything I need 88%
The manufacturer is easy to do business with 86%
Has the lowest complication rates among all U.S. implant brands 86%
Offers implants in width, projection & volume increments that meet all
84%
patient's needs
Is easy to use in surgery 73%
Has high strength cohesive gel that provides improved shape retention 69%
Provides good training and educational information to me / my practice 61%
The manufacturer is highly regarded on podium talks, papers, etc. 57%
The manufacturer brings innovative products to the market 57%
Is a brand I've never experienced a serious issue with 57%
Reference: January 2022: Sientra Market Research, data on file 15THE POWER OF THE SIENTRA RECON PORTFOLIO
Sientra has a portfolio of breast products that can help minimize potential disruptions and give control back to the surgeon
Common Complications The Benefit of Sientra Expanders & Implants
• Animation deformity
• Postoperative pain and • AlloX2: Revolutionary dual-port design and
Sub-pec discomfort integral drain allow for less invasive - non-
• Loss of pectoral function surgical - draining of serous fluid.
• Potential higher rupture rates • Sientra Silicone Gel Implants (HSC+): The
highest level of gel fracture resistance
• Seroma/infection available without the compromise of an
Pre-pec • Wrinkling and rippling overly firm implant1
• Healing complications
1. Kinney BM, Jeffers LLC, Ratliff GE, Carlisle DA. Silicone gel breast implants: science and testing. Plast Reconstr Surg. 2014;134(1S):47S-56S. 16WHAT MATTERS MOST TO AUG SURGEONS
2022
Importance in Selecting Top-2 Box n=71
Implant Brands
(Table Stakes) The manufacturer is easy to do business with 93%
Offers implants in width, projection & volume increments that meet all patient's
needs
90%
Manufacturer is consistent in having an available supply of everything I need 87%
Has the lowest complication rates among all U.S. implant brands 80%
Is easy to use in surgery 76%
Has the most comprehensive and longest warranty 76%
The manufacturer has attractive price points on its products 72%
Has a warranty that covers removal of an implant if the patient is unsatisfied with
their results for any reason
70%
Has high strength cohesive gel that provides improved shape retention 69%
Is a brand I've never experienced a serious issue with 66%
The manufacturer brings innovative products to the market 62%
• N=71, Augmentation Surgeon Sample. Base Sizes Shown by Survey Period.
• Q18/19: Please indicate how important each statement is when selecting a breast implant manufacturer for breast surgeries on a
Reference: January 2022: 17
scale of 1 Sientra Market
to 5. You Research,
can select data on from
any number file 1 to 5, where 1 means "Not at all Important" and 5 means "Extremely Important".HCP BUYING DRIVERS
TABLESTAKES
RECON: PRODUCT SUPERIORITY
1. Portfolio + breadth of sizes, 1. Training & education
widths, projections
2. Innovative products
3. Best in class warranty
2. Positive experience with,
safety of product
AUG: ADDED VALUE
1. Best in class warranty
3. Reliability of partner 2. Attractive price points
3. Innovative products and marketing
programs
Source: Sientra Consumer Market Research, 2022WHAT MATTERS MOST TO AUG PATIENTS =
WHAT MATTERS TO AUG SURGEONS
#1 #2
51%
49%
#3
43%
Category 1 Category 2 Category 3
Surgery
Procedure Cost Implant Safety
Complications
Reference: January 2022: Sientra Market Research, data on file 19MODERN DECISION MAKING FOR PLASTIC SURGERY
Empowered Consumers
50% 47% 39%
50% of patients do their 47% rely on 39% rely on their overall experience
own research ratings & reviews (doctor or office)
Reference: January 2022: Sientra Market Research, data on file 202022: AMPLIFIED CONSUMER CAMPAIGN
20 M+
Consumers Reached
500,000+
Patients Educated and Nurtured
80,000+
Search for SurgeonOUR PROMISE
SAFETY SECURITY
Unrivaled safety and clinical results. Sientra Peace-of-mind is everything. Sientra
offers the latest generation of implants with stands by our premium implants with the
low complication rates, so that you and industry’s most comprehensive
your patients can feel confident in your 20-year warranty.
choice with Sientra.
SATISFACTION SURGEONS
Exclusively available through BCPSs so
The highest rated silicone gel breast
patients can feel confident in the most
implant brand in the US. skilled and qualified hands.
*Realself.com Accessed February 2022
22A COMPANY OF FIRSTS
A STORY OF CONTINUOUS INNOVATION
First Shaped Implant
AlloX2 Pro – MRI
to Market in US
Compatible Tissue
Expander
Exclusive, Latest
Butterfly Strong Focus on
Generation, High
Partnership Reconstruction
Strength Gel
2021 2022
2012
AlloX2 – Only AuraGen – Fat
Tissue Grafting
First to Market Expander with System
Tabbed Tissue Integrated 2021
Expanders Aspiration Port
Dermaspan 2016
2007
24Building a Roadmap
Keeping up with the Evolution of Medical Knowledge
Replace and Regenerate
Understand Regenerative
Function and Enhance capabilities,
performance Implants tissue
Devices engineeringFOCUS
Breast Augmentation Breast Reconstruction Post-Op Management Non-Breast
• Natural looking • Best-in-class expansion • Treat and prevent • Full body
augmentation with safe options scarring transformation
and predictable • Aesthetic reconstruction • Promote healing and • Safe and predictable
outcomes with safe and predictable quick recovery solutions
• Complete portfolio for outcomes, with a natural
all breast needs look and feel
• Lead the next • Complete portfolio for all
generation of breast reconstruction
augmentation offering needs
• Innovative solutions for an
aesthetic breast
reconstruction
• Complication prevention
and management
26SIENTRA’S LONG-TERM STRATEGIC VISION YR. 5
NON-SILICONE
BREAST PRODUCTS
PORTFOLIO
ENHANCEMENTS
o Large Sizes NEXT GEN
o Complete implant BREAST EXPANSION
NON-BREAST
portfolio YR. 3 PRODUCTS
o Complete
expander portfolio
FAT GRAFTING
(non-breast)
o Small volume
options (face,
hands,…)
ADJACENCIES o Lumpectomy
YR. 1
options
o Solutions for post- o Body
op management
o Nipple recon
FAT GRAFTING
alternatives
(breast)
o Other implantable
devices used
during breast
ALLOX2 PRO surgery
(MRI-compatibility)
EXECUTION AND NEW PRODUCTS – REVENUE THE FUTURE – NON-BREAST
I N N O V AT I O N F R A M E W O R K G E N E R AT O R S + I N N O V AT I O NWHAT MAKES US DIFFERENT?
SIENTRA’S
PORTFOLIO
29PORTFOLIO
High-Strength Cohesive
Breast Tissue Expanders BIOCORNEUM® Softspan™
Silicone Gel Breast
for Breast Reconstruction Advanced Scar Treatment Extremity Expanders
Implants
• Available in 2 cohesive gel • Patented2 AlloX2® dual • #1 performing, preferred, • Allows for expansion of
options - HSC & HSC+ port design with integrated and recommended scar gel skin for local wound
• Unmatched shape retention drain improves clinical of plastic surgeons4 coverage
and softness, with highest outcomes3 • Only advanced scar • Widest array of options on
gel fracture resistance and • Dermaspan™ single port treatment with FDA- the market
gel-shell integration1 design for soft, cleared Silishield®
• Backed by best-in-class comfortable expansion patented crosslinked
Platinum20™ Warranty medical grade silicone and
SPF 305
1. Kinney et l., Silicone Gel Breast Implants: Science and Testing, Plast. Reconstr. Surg., 2014:134(1S):47S-56S
2. U.S. Patent Nos. 8,454,690 and 10,709,851
3. Fairchild et al., Safety and Efficacy of Smooth Surface Tissue Expander Breat Reconstruction, Aesth. Surg., 2020:40(1):53-62
4. Data on File. 30
5. U.S. Patent Nos. 5,741,509; 8,021,683; 8,802,133; 9,336,546; and 9,795,706DESIGN FEATURES UNIQUE TO ALL SIENTRA
IMPLANTS
Exclusive High-Strength Cohesive Gel Fill Level
Gel Optimal fill ratio
Engineered for shape retention and high designed
resistance to fracture, while maintaining to provide and maintain
a remarkably soft feel1 the desired breast shape
in combination with the
slope of the chest wall
Flat Back Design
Allows implants to conform to
the chest wall, creating a Highest Level of Gel-Shell
smooth lateral edge designed Integration
to limit palpability and Provides greater adherence of the gel
wrinkling fill to the shell, resulting in an implant
that maintains both strength and
softness 1
1. Kinney et l., Silicone Gel Breast Implants: Science and Testing, Plast. Reconstr. Surg., 2014:134(1S):47S-56S 31WHAT IS DIFFERENT ABOUT SIENTRA’S GEL
TECHNOLOGY?
It’s all about Chemistry!
Low Strength Silicone (non-Sientra) High Strength Silicone (Sientra only)
Pendant vinyl groups cause the polymers to run parallel to the End block vinyl groups allow for polymers to align perpendicular to
hydride cross-linkers, resulting in more compact and restricted the hydride cross-linkers, resulting in less restricted, more flexible
polymers. polymers.
32WHAT IS DIFFERENT ABOUT SIENTRA’S GEL
TECHNOLOGY?
It’s all about Chemistry!
Low Strength Silicone is like… High Strength Silicone is like…
Parallel Aligned Random Alignment of
Collagen Fibers Collagen Fibers
Of Scar Tissue Of Normal Dermis
(more rigid, less (more flexible,
tensile strength) high tensile strength)
SCAR DERMIS
Pendant vinyl groups cause the polymers to run parallel to the End block vinyl groups allow for polymers to align perpendicular to
hydride cross-linkers, resulting in more compact and restricted the hydride cross-linkers, resulting in less restricted, more flexible
polymers. polymers.
33OPTIMAL BALANCE BETWEEN STRENGTH AND
SOFTNESS
Gel strength and softness of all implant
types.1
Sientra implants are remarkably strong,
yet soft to the touch.
Sientra implants show minimum trade-off
in softness in order to achieve greater
gel strength.
1. Kinney et l., Silicone Gel Breast Implants: Science and Testing, Plast. Reconstr. Surg., 2014:134(1S):47S-56S 34UNRIVALED SAFETY AND CLINICAL DATA
*
4
*The clinical studies from these manufacturers are not
designed to be compared head-to-head. Each individual
company’s own individual and published rates were
presented
1Stevens WG, Calobrace MB, Alizadeh A, Zeidler KR,
Harrington JL, d’Incelli RC. Ten-year core study data for
Sientra’s Food and Drug Administration - approved round
and shaped breast implants with cohesive silicone gel. Plast
Reconstr Surg. 2018;141(4S):7S-19S.
2Mentor Worldwide LLC. Patient Decision Checklist:
MemoryShape & MemoryGel:
https://www.breastimplantsbymentor.com/MENTOR-
implant-safety-information. Accessed December 2021
3Allergan Sales, LLC. Patient Decision Checklist:
https://www.natrellesurgeon.com/Content/PDF/Augmentati
on_Consent_Form.pdf. Accessed December 2021
4Sientra, Inc. Patient Decision Checklist:
https://sientra.com/app/uploads/2021/10/MDC-0748-R2-
Patient-Decision-Checklist-AUG-v1.pdf. Accessed April 2022
35SIENTRA’S
WARRANTY
36SIENTRA PLATINUM20™, THE BEST WARRANTY IN
THE INDUSTRY
LIFETIME FREE implant replacement for implant rupture (any size or style)
20 Year Up to $5,000 for uncovered fees and costs due to implant rupture
20 Year FREE implant replacement for complications of capsular contracture
(Baker Grade III/IV), late forming seroma and double capsule
2 Year Up to $2,000 for uncovered fees and costs due to capsular contracture
(Baker Grade III/IV), late forming seroma and double capsule
37ALLOX2 PLATFORM
TISSUE EXPANDER LINES
AlloX2 Dermaspan Softspan Extremity
ExpandersALLOX2 – ELEVATING PATIENT CARE
PLATFORM FOR THE
ONLY TISSUE EXPANDER PUBLISHED EVIDENCE ON
FUTURE OF EXPANSION
WITH DRAIN PORT CLINICAL BENEFITS
TECHNOLOGY
Integrated drain for post-op “The unique feature of the AlloX2 Addressing pain points with
aspiration and access to the provides surgeons easy access to current expansion options.
periprosthetic space. the periprosthetic space without
altering any of the other
characteristics of a tissue
expander. This resulted in a
reduced time to drain removal
and facilitated management of
postoperative seroma and
infection.”1
40
1 Momeni et al., The Impact of Device Innovation on Clinical Outcomes in Expander-based Breast Reconstruction, Plast. Reconstr. Surg. 2020: 7(12)ALLOX2 PLATFORM
EVOLUTION
ALLOX2 PRO
41ALLOX2 PRO FEATURES AND BENEFITS
6 Suture Tabs
• Better fixation
Nonmetallic Ports and
Reduced Magnet Size:
• MRI compatibility
• Reduced image artifacts in CT’s Improved Depth Location
• Less interference with • Precise and easy location
radiotherapy treatment of fill and drain ports
Anatomical shape
Handheld device
• Softer feel for
patient comfort • Convenient port
location
Unique, Proprietary Drain for Seroma Aspiration
• Soft and pliable drain for easy insertion and removal
• Published evidence on benefits of drain’s ability for fluid
aspiration, diagnostic sampling, pocket irrigation, and
antibiotic delivery.ALLOX2 PRO KEY DIFFERENCES
AlloX2 AlloX2 Pro
Ports (fill and drain) 2 Titanium Ports 2 Peek Ports
(metallic) (plastic)
Magnet(s) 2 1 superficial
(1 inside each port - 2.66 cm3) (0.30 cm3)
Metal 6.01 cm3 0.36 cm3
(94% reduction)
MRI Compatibility No Yes
Imaging/Radiation Interference Standard Reduced
Fixation Tabs 3 6
Fill/Drain Ports’ Needles 21/18 gauge 18/18 gauge
Port Location Magnetic Port Locator Magnetic Port Locator OR PortFinder
Patient Comfort Standard Softer and more pliable
Surface Smooth and Textured SmoothAURAGEN
44SIENTRA + AURAGEN: TOTAL BODY TRANSFORMATION,
THE NEXT WAVE IN AESTHETICS
Total Body Transformation
Fat is “relocated” from unwanted areas • Broadens opportunity in plastic surgery
to add volume where desired. Minimal
OR time, using one’s own tissue. market with addition of highly
differentiated, FDA-cleared fat grafting
technology
• Drives additional revenue growth and TAM
Art Science opportunity in Sientra’s core breast
aesthetics market
Natural Looking Long-Lasting,
Ultimate sculpting predictable results
tool with flexibility to Evidence of high fat • Expands Sientra’s TAM opportunity through
create desired retention, fat
outcomes concentration, and addition of non-breast aesthetic
cell viability1,2 applications – including the significant
market for face, hands and body
1 An et al., Comparative Analysis of Two Automated Fat-processing Systems, Plast. Reconstr. Surg. - Global Open: January 2020 - Volume 8 - Issue 1 - p e2587
2 Phase I Gluteal Augmentation Study – Independent Investigator Study. Data on File.
45FAT GRAFTING NATURALLY ALIGNS WITH SIENTRA’S CORE BREAST
BUSINESS AND EXPANDS INTO NEW AESTHETIC MARKETS
Additional
Revenue Bundling
from Existing Opportunity
Accounts
Door Opener Convert New
with Product Accounts
Differentiation
Non-Breast Revenue from
Plastic Breast Procedures reduction without implants, implant
gluteal augmentation,
Surgery where Implants removal, autologous reconstruction
body, face, hands Applications are not UsedFAT GRAFTING IS TRENDING IN MEDIA COVERAGE
OF BREAST PROCEDURES
47CLINICAL BENEFITS OF FAT GRAFTING IS SUBJECT OF
INCREASED STUDY
48ROADMAP TO LAUNCH
Commercial Design + BTS – Market Seeding /
Manufacturing Scale Up Soft Launch
Q4 2021 2022 Q1 2023
200 Patients Clinical Study
• Main Endpoint: Fat Retention at 12 months
• 10 sites
• 100 Recon / 100 Augmentation
Acquisition
Launch
492022 – A YEAR OF LAUNCHES
PLANNED LAUNCHES
Q1 2022 2022 2022 Q1 2023
Dermaspan Low Profile AlloX2 Pro + Fat Grafting
6 tabs Plus PortFinder System
Implants
Product Portfolio New Product New Product
Improvement Enhancement
51SIENTRA’S LONG-TERM STRATEGIC VISION YR. 5
NON-SILICONE
BREAST PRODUCTS
NEXT GEN
NON-BREAST EXPANSION
YR. 3 PRODUCTS
FAT GRAFTING
(non-breast)
PORTFOLIO
ADJACENCIES ENHANCEMENTS
YR. 1
FAT GRAFTING
(breast)
ALLOX2 PRO Innovation backed up by science and clinical data
(MRI-compatibility)
Beyond breast – Full Body Transformation
EXECUTION AND NEW PRODUCTS – REVENUE THE FUTURE – NON-BREAST
I N N O V AT I O N F R A M E W O R K G E N E R AT O R S + I N N O V AT I O NHOW DOES THIS FIT INTO THE FINANCIAL MODEL?
FY 2021 REVIEW
$ Millions
2019 2020 2021 21 V 20 21 V 20
$ Change % Change
Global Net Sales 46.4 55.0 81.5 26.5 48%
COGS 16.4 23.6 35.9 (12.3) -52%
Gross Margin 30.0 31.4 45.6 14.2 45%
GM % 64.7% 57.1% 55.9%
Operating Expense
S&M 35.5 37.4 44.9 (7.5) -20%
R&D 9.2 8.7 8.7 0.0 0%
G&A 35.0 32.3 25.0 7.3 23%
Total Non-GAAP Op Ex 79.7 78.4 78.6 (0.1) 0%
Non-GAAP EBITDA (49.7) (47.0) (33.0) 14.1 30%
542022 FOCUS AND FUTURE PERSPECTIVE
$200M SIEN Pathway Perspective
2024+
Revenue NG Op Ex Op Profit
55CORPORATE FOCUS
• A leader in Reconstruction
• Grow into a full Aesthetic Company
• Double our revenue in the next 3 years
56QUESTIONS?
57You can also read
